Christensen, L., Roager, H
Common GLP-1 medications prescribed in 2025 include: Semaglutide (Wegovy, Ozempic) Tirzepatide (Mounjaro) Liraglutide (Saxenda) Peer-reviewed clinical trials published in journals such as The New England Journal of Medicine and JAMA document average body weight reductions of approximately 1022% over 612 months when GLP-1 medications are combined with lifestyle support and ongoing physician oversight
Furthermore, many of the metabolic improvements, particularly those related to insulin sensitivity and cardiovascular health, persist partially even with some weight regain
The information and other content provided in this material is of a general nature and is not intended and should not be construed as medical advice, nor is the information a substitute for professional advice provided by a medical doctor or certified health provider.
During this initial consultation, lab work is reviewed, and a personalized treatment plan is developed, which may include prescribing GLP-1 medications such as semaglutide or tirzepatide
2018 Feb;32(2):305-311